JP2023527794A5 - - Google Patents

Info

Publication number
JP2023527794A5
JP2023527794A5 JP2022572329A JP2022572329A JP2023527794A5 JP 2023527794 A5 JP2023527794 A5 JP 2023527794A5 JP 2022572329 A JP2022572329 A JP 2022572329A JP 2022572329 A JP2022572329 A JP 2022572329A JP 2023527794 A5 JP2023527794 A5 JP 2023527794A5
Authority
JP
Japan
Prior art keywords
cancer
product according
pharmaceutical product
subject
trastuzumab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022572329A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023527794A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/034715 external-priority patent/WO2021243123A1/en
Publication of JP2023527794A publication Critical patent/JP2023527794A/ja
Publication of JP2023527794A5 publication Critical patent/JP2023527794A5/ja
Pending legal-status Critical Current

Links

JP2022572329A 2020-05-29 2021-05-28 トラスツズマブ及びオキサリプラチン系化学療法と組み合わせたツカチニブによるher2陽性癌を治療する方法 Pending JP2023527794A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063032223P 2020-05-29 2020-05-29
US63/032,223 2020-05-29
PCT/US2021/034715 WO2021243123A1 (en) 2020-05-29 2021-05-28 Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab and an oxaliplatin-based chemotherapy

Publications (2)

Publication Number Publication Date
JP2023527794A JP2023527794A (ja) 2023-06-30
JP2023527794A5 true JP2023527794A5 (cg-RX-API-DMAC7.html) 2024-05-29

Family

ID=76601765

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022572329A Pending JP2023527794A (ja) 2020-05-29 2021-05-28 トラスツズマブ及びオキサリプラチン系化学療法と組み合わせたツカチニブによるher2陽性癌を治療する方法

Country Status (10)

Country Link
US (1) US20230173067A1 (cg-RX-API-DMAC7.html)
EP (1) EP4157257A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023527794A (cg-RX-API-DMAC7.html)
KR (1) KR20230027068A (cg-RX-API-DMAC7.html)
CN (1) CN115768416A (cg-RX-API-DMAC7.html)
AU (1) AU2021281336A1 (cg-RX-API-DMAC7.html)
CA (1) CA3183592A1 (cg-RX-API-DMAC7.html)
IL (1) IL298538A (cg-RX-API-DMAC7.html)
MX (1) MX2022014886A (cg-RX-API-DMAC7.html)
WO (1) WO2021243123A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202428307A (zh) * 2022-10-12 2024-07-16 日商中外製藥股份有限公司 包含胜肽、界面活性劑及聚合物的組成物
WO2024130003A1 (en) * 2022-12-15 2024-06-20 Bolt Biotherapeutics, Inc. Cancer combination treatment method
CN117224689B (zh) * 2023-11-16 2024-02-23 上海复宏汉霖生物技术股份有限公司 联合抗her2抗体和化疗剂治疗胃癌的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
KR102000312B1 (ko) 2011-10-14 2019-07-15 어레이 바이오파마 인크. Erb2 (her2) 저해제의 고체 분산물
US9168254B2 (en) 2011-10-14 2015-10-27 Array Biopharma Inc. Polymorphs of ARRY-380, a selective HER 2 inhibitor and pharmaceutical compositions containing them
KR20180048804A (ko) * 2015-09-04 2018-05-10 아슬란 파마슈티컬스 피티이 엘티디 바리티닙 및 항암제를 포함하는 병용 요법
HUE064898T2 (hu) * 2017-03-02 2024-04-28 Genentech Inc HER2-pozitív emlõrák adjuváns kezelése
EP3615067A1 (en) * 2017-04-28 2020-03-04 Seattle Genetics, Inc. Treatment of her2 positive cancers
SG11202005613SA (en) * 2017-12-19 2020-07-29 Abraxis Bioscience Llc Methods of treating colon cancer using nanoparticle mtor inhibitor combination therapy

Similar Documents

Publication Publication Date Title
CN111065411B (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
JP2023502929A5 (cg-RX-API-DMAC7.html)
JP2023534009A5 (cg-RX-API-DMAC7.html)
CN108601831B (zh) 一种抗pd-1抗体和vegfr抑制剂联合在制备治疗癌症的药物中的用途
Higuchi et al. Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2)
JP2020517696A5 (cg-RX-API-DMAC7.html)
Abdel-Rahman Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside
JP2012509889A5 (cg-RX-API-DMAC7.html)
TWI641385B (zh) 抗腫瘤劑及抗腫瘤效果增強劑
JP2012522837A5 (cg-RX-API-DMAC7.html)
US20210015787A1 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
JP2023533937A5 (cg-RX-API-DMAC7.html)
JP2022523045A5 (cg-RX-API-DMAC7.html)
KR20240130081A (ko) 항-trop-2 항체-약물 접합체와 추가 치료제의 병용 사용
JP2023537676A5 (cg-RX-API-DMAC7.html)
Umemura et al. Modified FOLFIRINOX for locally advanced and metastatic pancreatic cancer patients resistant to gemcitabine and S-1 in Japan: a single institutional experience
JP2022553041A5 (cg-RX-API-DMAC7.html)
Camera et al. MOMENTUM: a phase I trial investigating 2 schedules of capecitabine with aflibercept in patients with gastrointestinal and breast cancer
JP6458007B2 (ja) 抗腫瘍性白金錯体を含有する抗腫瘍剤及び抗腫瘍効果増強剤
Hannan 367eP Phase II trial of FTD/TPI and nal-IRI in advanced PDAC
BR112020011796A2 (pt) uso de tratamento combinado de anticorpo pd-1 e apati-nib para o tratamento de câncer de mama negativo triplo
CN112543637B (zh) 伊立替康联合免疫检查点抑制剂和5-fu在制备治疗肿瘤疾病的药物中的用途
WO2026046410A1 (zh) 一种抗体药物偶联物与免疫检查点抑制剂的组合
Habib et al. A Case of Advanced Multifocal Cholangiocarcinoma With Excellent Response to Pembrolizumab
Jelinek et al. A phase I trial adding poly (ADP-ribose) polymerase inhibitor veliparib to induction